Jonathan Symonds Acquires 5,000 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 5,000 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were purchased at an average cost of GBX 1,951 per share, with a total value of £97,550.

Jonathan Symonds also recently made the following trade(s):

• On Thursday, February 5th, Jonathan Symonds bought 2,500 shares of GSK stock. The stock was purchased at an average price of GBX 2,114 per share, for a total transaction of £52,850.

GSK Stock Performance

Shares of GSK opened at GBX 1,966.50 on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. The firm’s fifty day simple moving average is GBX 2,028.25 and its two-hundred day simple moving average is GBX 1,824.21. GSK plc has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,282. The stock has a market capitalization of £78.88 billion, a P/E ratio of 14.17, a price-to-earnings-growth ratio of 1.24 and a beta of 0.32.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, analysts predict that GSK plc will post 175.980975 EPS for the current year.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Senior insider buying: Chief Director Jonathan Symonds purchased 5,000 shares at ~GBX 1,951 (~£97,550), signaling confidence from management; smaller buys from Wendy Becker (411 shares at GBX 1,963) and Anne Beal (196 shares reported) add to the signal that insiders see value — insider purchases often support share-price sentiment.
• Positive Sentiment: Wendy Becker insider purchase reported. GSK (LON:GSK) Insider Wendy Becker Purchases 411 Shares
• Positive Sentiment: Share buyback activity: GSK repurchased 560,000 ordinary shares on 20 March, increasing treasury holdings and reducing free float — buybacks support EPS and can be a direct driver of upward price pressure. GSK expands share buyback, lifts treasury holdings and updates voting rights
• Positive Sentiment: Regulatory milestone: GSK’s lung‑cancer treatment received orphan‑drug designation in Japan, which can offer regulatory incentives, market exclusivity and an accelerated development path in that market — a favorable clinical/regulatory development that supports long‑term value. GSK’s lung cancer treatment secures “orphan drug” status in Japan
• Neutral Sentiment: Employee share issuance: GSK admitted 96,525 new ordinary shares to the LSE under employee share plans — standard compensation-related issuance that causes modest dilution but is routine and typically neutral for near‑term valuation. GSK Adds 96,525 Shares to LSE Listing Under Employee Share Plans

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GSK shares. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research note on Wednesday, January 7th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 2,300 price objective on shares of GSK in a research report on Wednesday, February 4th. Citigroup lifted their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research report on Thursday, January 15th. Finally, UBS Group reiterated a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.